Publications by authors named "T Kvien"
Background: Targeted therapies have been associated with potential risk of malignancy, which is a common concern in daily rheumatology practice in patients with inflammatory arthritis (IA) and a history of cancer.
Objectives: To perform a systematic literature review to inform a Task Force formulating EULAR points to consider on the initiation of targeted therapies in patients with IA and a history of cancer.
Methods: Specific research questions were defined within the Task Force before formulating the exact research queries with a librarian.
Background: Potential associations between targeted therapies and a new cancer in patients with inflammatory arthritis (IA) and a previous malignancy are a frequent concern in daily rheumatology practice.
Objectives: To develop points to consider (PTC) to assist rheumatologists when initiating a targeted therapy in the context of a previous malignancy.
Methods: Following EULAR standardised operating procedures, a task force met to define the research questions for a systematic literature review and to formulate the overarching principles (OPs) and the PTC.
Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.
Lancet Reg Health Eur
January 2025
Background: As most people now have established hybrid immunity, the need for regular, updated SARS-CoV-2 vaccine boosters in patients with immune-mediated inflammatory diseases (IMIDs) is unclear. The study aim was to assess humoral and cellular immunogenicity of a fifth bivalent vaccine dose in patients with IMID on tumour necrosis factor inhibitors (TNFi).
Methods: In the longitudinal, observational Nor-vaC study, we assessed anti-spike and neutralising antibodies against Wuhan, Omicron BA.
Article Synopsis
- - The research aimed to assess data collection practices for non-musculoskeletal manifestations (NMMs), comorbidities, and safety outcomes in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) across 17 European registries, emphasizing the need for international collaboration for better treatment strategies.
- - A comprehensive survey with over 4,400 questionnaire items examined how 58 defined conditions were recorded in each registry, focusing on recording methods and the ability to link data to national registries.
- - The study found that while many registries recorded a variety of conditions consistently, Nordic countries showed potential for data linkage but had limited recording practices, while other regions maintained thorough documentation, paving the way
Objective: Systemic sclerosis Impact of Disease (ScleroID) is the first comprehensive patient-reported outcome measure (PROM) specifically developed for systemic sclerosis (SSc). We investigated the performance of ScleroID in patients with diffuse cutaneous SSc (dcSSc), as a prerequisite for its use in randomised controlled trials (RCTs) testing potentially disease-modifying drugs.
Methods: All patients with dcSSc from the large, multicentric, ScleroID cohort were included.